Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18825441 | 0.93 | GPR119 (0.44) | GPR119ACACBKCNH2 | |
| SCHEMBL18825463 | 0.92 | GPR119 (0.44) | GPR119ACACBKCNH2 | |
| SCHEMBL18825471 | 0.91 | GPR119 (0.43) | GPR119GABRA5ACACBKCNH2 | |
| SCHEMBL18825339 | 0.91 | GPR119 (0.43) | GPR119ACACBKCNH2 | |
| SCHEMBL18825515 | 0.91 | GPR119 (0.43) | GPR119GABRA5ACACBKCNH2 | |
| SCHEMBL18843757 | 0.88 | GPR119 (0.46) | GPR119ACACB | |
| SCHEMBL18825473 | 0.88 | GPR119 (0.42) | GPR119KCNH2NPC1MAPTMAPK1 | |
| SCHEMBL18825438 | 0.87 | GPR119 (0.47) | GPR119KCNH2NPC1 | |
| SCHEMBL18825493 | 0.86 | GPR119 (0.44) | GPR119ACACBMAPTMAPK1 | |
| SCHEMBL18825452 | 0.86 | GPR119 (0.40) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | claimed |
| US-20180318274-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2018-11-08 | — | — | US | claimed |
| EP-3352750-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2018-08-01 | — | — | EP | claimed |
| WO-2017078352-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2017-05-11 | — | — | WO | claimed |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | HYUNDAI PHARM CO., LTD. (KR) | 2020-07-28 | — | — | US | disclosed |
| US-20180318274-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2018-11-08 | — | — | US | disclosed |
| EP-3352750-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017078352-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2017-05-11 | — | — | WO | disclosed |
| WO-2017078352-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2017-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723699-B2 | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | GPR119, GLP1R, GCGR | GPR119 1/4885GABRA5 2008/4885ACACB 632/4885 |
| US-20180318274-A1 | CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT | GPR119, GLP1R, GCGR | GPR119 1/4885GABRA5 2008/4885ACACB 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.